# Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

> **NCT03549689** · PHASE2 · WITHDRAWN · sponsor: **Philip Grant**

## Conditions studied

- HIV/AIDS
- HIV-1-infection
- Osteopenia

## Interventions

- **DRUG:** Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
- **DRUG:** Current tenofovir alafenamide (TAF)-containing ART regimen

## Key facts

- **NCT ID:** NCT03549689
- **Lead sponsor:** Philip Grant
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn by drug manufacturer
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03549689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03549689, "Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03549689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*